Antiphospholipid antibodies as risk factors for cardiovascular lesions in patients with antiphospholipid syndrome

Shevchuk S.V.¹, Segeda U.S. ², Kuvikova I.P. ³

• ¹National Pirogov Memorial Medical University, Vinnytsya
• ²Науково-дослідний інститут реабілітації інвалідів (навчально-науково-лікувальний комплекс) Вінницького національного медичного університету ім. М.І. Пирогова
• ³Науково-дослідний інститут реабілітації інвалідів Вінницького національного медичного університету ім. М.І. Пирогова, Вінниця

Summary. Summary. The article presents data on the prevalence of different classes of antiphospholipid antibodies in the Ukrainian population of patients with primary and secondary antiphospholipid syndrome, their relationship with disease activity and cardiovascular damage. It was revealed that elevated levels of anticardiolipin antibodies IgG class and antibeta-2 GP 1 antibodies are found respectively in 73.5 and 85.3% of patients with PAPS and 68.7 and 83.3% of patients with SAPS and 6.8 and 9% healthy people respectively. Hyperproduction of antiphospholipid antibodies in patients with APS weakly depends on the age of patients and did not correlate with gender and duration of disease but closely associated with the severity of organ damage and disease activity. Increase levels of anticardiolipin antibodies and anti-beta-2 GP 1 antibodies in patients with PAPS and SAPS closely associated with cardiovascular damage, while the combination of several classes of antibodies does not correlate with the frequency of clinical and subclinical manifestations of atherosclerotic lesions.